Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

kreftslag Sep. 23 at 4:58 AM

$OMER +14% yesterday on the Cantor upgrade (Neutral → Overweight, $22 PT). Market is finally pricing in what the Yartemlea launch data has been showing. Needham's HOLD is starting to look stale. When your bear case gets outrun by the tape and the sell-side starts moving in your favor, that's usually the signal, not the outlier. Question isn't if Needham revisits the model — it's how long they wait to admit it.

0 · Reply

TheNewAxe Sep. 23 at 4:15 AM

$OMER $AMD $MU Hit new ATH today and yesterday! Last high was June 30th. Up 275% YTD. 🚀💥🚀💥🚀💥

0 · Reply

uptech Sep. 23 at 1:30 AM

$OMER Well, that was fun. Now for the hangover. Expect some backing and filling before the next runup before the November numbers. Plenty of games to be played before then. Expect it.

4 · Reply

resq1 Sep. 23 at 12:39 AM

$OMER triple digits by q2 '27?

1 · Reply

uptech Sep. 22 at 11:36 PM

$OMER No, he is ahead of the curve and allowing room to increase PT. IMO.

1 · Reply

topstockalerts Sep. 22 at 11:00 PM

$OMER the market is showing this stock a lot of respect.

0 · Reply

TRYII Sep. 22 at 10:46 PM

$OMER

0 · Reply

MrLucky123 Sep. 22 at 10:44 PM

$OMER cantor analyst a douche bag.

2 · Reply

MayorofMNKD Sep. 22 at 10:38 PM

$OMER

4 · Reply

uptech Sep. 22 at 10:36 PM

$OMER uptech Jun 3 @mendergill Who is losing patience? I'm buying. 3 prototyper Jun 3 $OMER Under $10 is buy from me 1 4 uptech Jun 3 @prototyper don't wait for pennies. Look at the stochastics 1

0 · Reply

Cantor upgrades Omeros on better than expected Yartemlea launch

2026-09-22T10:05:21.000Z - 22 hours ago

Omeros upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-08-17T08:54:06.000Z - 5 weeks ago

Omeros reports Q2 adjusted EPS 2c vs (24c) last year

Aug 12, 2026, 4:30 PM EDT - 5 weeks ago

Omeros Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 5 weeks ago

Omeros Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 5 weeks ago

Omeros Quarterly report: Q2 2026

Aug 12, 2026, 4:02 PM EDT - 5 weeks ago

Omeros Corporation Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 8:00 AM EDT - 6 weeks ago

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

2026-08-03T12:41:41.000Z - 7 weeks ago

Omeros grants new technology add-on payment status to Yartemlea

Aug 3, 2026, 8:30 AM EDT - 7 weeks ago

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

2026-07-27T14:15:25.000Z - 1 month ago

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

AZN

2026-07-27T14:15:17.000Z - 1 month ago

Omeros up 11% to $10.89 after AstraZeneca study failure

AZN

Jul 13, 2026, 2:16 PM EDT - 2 months ago

Omeros Corporation Investigated by the Portnoy Law Firm

Jun 26, 2026, 2:11 PM EDT - 2 months ago

Omeros stock crashes on regulatory setback: buy the dip?

2026-06-26T15:30:11.000Z - 2 months ago

Omeros price target lowered to $33 from $40 at H.C. Wainwright

2026-06-26T12:35:20.000Z - 2 months ago

Omeros announces CHMP adopts negative opinion on MAA for narsoplimab

Jun 26, 2026, 8:30 AM EDT - 2 months ago

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

Jun 18, 2026, 1:00 PM EDT - 3 months ago

Omeros Transcript: AGM 2026

Jun 15, 2026, 8:30 AM EDT - 3 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

2026-06-12T13:45:42.000Z - 3 months ago

Omeros trading resumes

2026-06-12T13:35:42.000Z - 3 months ago

Omeros trading halted, volatility trading pause

May 13, 2026, 4:30 PM EDT - 4 months ago

Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 4 months ago

Omeros Quarterly report: Q1 2026

2026-05-13T20:27:08.000Z - 4 months ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 4 months ago

Omeros Corporation Reports First Quarter 2026 Financial Results

May 11, 2026, 4:02 PM EDT - 4 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 4 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Omeros Proxy statement: Proxy filing

2026-04-16T14:14:18.000Z - 5 months ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 5 months ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Annual report: Q4 2025

Mar 31, 2026, 4:02 PM EDT - 5 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 6 months ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 6 months ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Feb 17, 2026, 8:45 AM EST - 7 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Jan 27, 2026, 9:00 AM EST - 7 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 7, 2026, 6:50 PM EST - 8 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 8 months ago

Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 8 months ago

Omeros Press release: FDA Announcement

Dec 26, 2025, 6:36 PM EST - 9 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025, 9:05 AM EST - 9 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 9 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025, 8:30 AM EST - 9 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:11 PM EST - 10 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 10 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 16, 2025, 8:30 AM EDT - 11 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 11 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 11 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 11 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 11 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 1 year ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 1 year ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

kreftslag Sep. 23 at 4:58 AM

0 · Reply

TheNewAxe Sep. 23 at 4:15 AM

$OMER $AMD $MU Hit new ATH today and yesterday! Last high was June 30th. Up 275% YTD. 🚀💥🚀💥🚀💥

0 · Reply

uptech Sep. 23 at 1:30 AM

$OMER Well, that was fun. Now for the hangover. Expect some backing and filling before the next runup before the November numbers. Plenty of games to be played before then. Expect it.

4 · Reply

resq1 Sep. 23 at 12:39 AM

$OMER triple digits by q2 '27?

1 · Reply

uptech Sep. 22 at 11:36 PM

$OMER No, he is ahead of the curve and allowing room to increase PT. IMO.

1 · Reply

topstockalerts Sep. 22 at 11:00 PM

$OMER the market is showing this stock a lot of respect.

0 · Reply

TRYII Sep. 22 at 10:46 PM

$OMER

0 · Reply

MrLucky123 Sep. 22 at 10:44 PM

$OMER cantor analyst a douche bag.

2 · Reply

MayorofMNKD Sep. 22 at 10:38 PM

$OMER

4 · Reply

uptech Sep. 22 at 10:36 PM

$OMER uptech Jun 3 @mendergill Who is losing patience? I'm buying. 3 prototyper Jun 3 $OMER Under $10 is buy from me 1 4 uptech Jun 3 @prototyper don't wait for pennies. Look at the stochastics 1

0 · Reply

costrexx Sep. 22 at 10:32 PM

$OMER I think their estimate is lower than what will happen. Either way we are good. Omeros isn’t about one drug According to The Fly, Cantor upgraded Omeros to ‘Overweight’ from ‘Neutral’ with a $22 price target. After speaking with physicians, the firm said it is “increasingly convinced” that the drug could become larger than previously expected, with the potential to capture 30% to 40% of its market. Cantor raised its peak sales estimate to $400 million.

1 · Reply

topstockalerts Sep. 22 at 10:18 PM

$OMER the market seems to want this higher, plain and simple.

0 · Reply

KingZack25 Sep. 22 at 10:15 PM

$OMER wonder how many people they shook out when this dumped to high 6's. I don't feel bad for those left behind. Gotta know what you own and buy the dips

1 · Reply

MikeLogan Sep. 22 at 10:00 PM

$OMER Our baby girl it's 21 today, somebody buy her a cocktail 🍸🍹

1 · Reply

siserv2001 Sep. 22 at 9:51 PM

$OMER Wow, What an OMER day today! Cantor Fitzgerald upgrades to overweight from Neutral. Did anyone see their price target? What ever happened to that B of A Analyst? Gotta love today's action and finally OMER gets a little respect! Congratulations to all the longs! Glad I added to my closely guarded stash!

1 · Reply

crypto_minute Sep. 22 at 9:48 PM

$OMER well here for 10 more..

0 · Reply

uptech Sep. 22 at 9:47 PM

$OMER Generational wealth. Ponder it.

1 · Reply

Phase3 Sep. 22 at 9:42 PM

$OMER ........ https://stockcharts.com/freecharts/pnf.php?c=omer,PWTADANRNO[PA][D][F1!3!!!2!20]

0 · Reply

TarponTime Sep. 22 at 9:29 PM

$OMER The Tarpon Take is this …. “Bloomberg Symphony” numbers were all bullshit??? meant to lower the SP to help the shorts and improve buying opportunities??

2 · Reply

TarponTime Sep. 22 at 9:22 PM

$OMER Wolf Block

1 · Reply

guinnessnu Sep. 22 at 9:15 PM

Would you sell a portion of $AUPH to increase $OMER at this stage?

1 · Reply

AndreasD Sep. 22 at 9:11 PM

$OMER $OMER Anyone missing our former CMO or CCO since they left Omeros? I certainly am not. Immaterial ! Way to go, Greg & the management team — consistently proving Wall Street wrong. Let’s rake it in in Europe in a month’s time & surprise the market once again with booming Q3 sales. My little guess, FWIW: $47M. Maybe even a little guidance for our first quarter with NTAP to really get the rocket going? 🚀

2 · Reply

Market Cap	1.34B
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	6.55
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.89

Volume	3,958,000
Avg Vol	1,933,292
Day's Range	N/A - N/A
Shares Out	72.39M
Stochastic %K	96%
Beta	2.60
Analysts	Sell
Price Target	$44.00